These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23343182)

  • 41. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.
    Jeromin S; Weissmann S; Haferlach C; Dicker F; Bayer K; Grossmann V; Alpermann T; Roller A; Kohlmann A; Haferlach T; Kern W; Schnittger S
    Leukemia; 2014 Jan; 28(1):108-17. PubMed ID: 24113472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.
    Zent CS; Burack WR
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):119-24. PubMed ID: 25696844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
    Guièze R; Robbe P; Clifford R; de Guibert S; Pereira B; Timbs A; Dilhuydy MS; Cabes M; Ysebaert L; Burns A; Nguyen-Khac F; Davi F; Véronèse L; Combes P; Le Garff-Tavernier M; Leblond V; Merle-Béral H; Alsolami R; Hamblin A; Mason J; Pettitt A; Hillmen P; Taylor J; Knight SJ; Tournilhac O; Schuh A
    Blood; 2015 Oct; 126(18):2110-7. PubMed ID: 26316624
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
    Tausch E; Beck P; Schlenk RF; Jebaraj BJ; Dolnik A; Yosifov DY; Hillmen P; Offner F; Janssens A; Babu GK; Grosicki S; Mayer J; Panagiotidis P; McKeown A; Gupta IV; Skorupa A; Pallaud C; Bullinger L; Mertens D; Döhner H; Stilgenbauer S
    Haematologica; 2020 Oct; 105(10):2440-2447. PubMed ID: 33054084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells.
    Wu X; Tschumper RC; Jelinek DF
    Leukemia; 2013 Nov; 27(11):2264-7. PubMed ID: 23685408
    [No Abstract]   [Full Text] [Related]  

  • 46. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia.
    Schwaederlé M; Ghia E; Rassenti LZ; Obara M; Dell'Aquila ML; Fecteau JF; Kipps TJ
    Leukemia; 2013 Apr; 27(5):1214-7. PubMed ID: 23337928
    [No Abstract]   [Full Text] [Related]  

  • 47. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
    Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN
    Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recurrent gene mutations in CLL.
    Martínez-Trillos A; Quesada V; Villamor N; Puente XS; López-Otín C; Campo E
    Adv Exp Med Biol; 2013; 792():87-107. PubMed ID: 24014293
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Pozzo F; Bittolo T; Tissino E; Vit F; Vendramini E; Laurenti L; D'Arena G; Olivieri J; Pozzato G; Zaja F; Chiarenza A; Di Raimondo F; Zucchetto A; Bomben R; Rossi FM; Del Poeta G; Dal Bo M; Gattei V
    Haematologica; 2021 Dec; 106(12):3125-3135. PubMed ID: 33121237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
    Dal Bo M; Bulian P; Bomben R; Zucchetto A; Rossi FM; Pozzo F; Tissino E; Benedetti D; Bittolo T; Nanni P; Cattarossi I; Zaina E; Chivilò H; Degan M; Zaja F; Pozzato G; Chiarenza A; Di Raimondo F; Del Principe MI; Del Poeta G; Rossi D; Gaidano G; Gattei V
    Leukemia; 2016 Oct; 30(10):2011-2018. PubMed ID: 27109509
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genomic data integration in chronic lymphocytic leukemia.
    Fernández-Martínez JL; deAndrés-Galiana EJ; Sonis ST
    J Gene Med; 2017 Jan; 19(1-2):. PubMed ID: 27928896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
    Bhoi S; Baliakas P; Cortese D; Mattsson M; Engvall M; Smedby KE; Juliusson G; Sutton LA; Mansouri L
    Haematologica; 2016 Feb; 101(2):e63-5. PubMed ID: 26589911
    [No Abstract]   [Full Text] [Related]  

  • 53. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
    Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
    Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acquired initiating mutations in early hematopoietic cells of CLL patients.
    Damm F; Mylonas E; Cosson A; Yoshida K; Della Valle V; Mouly E; Diop M; Scourzic L; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kikushige Y; Davi F; Lambert J; Gautheret D; Merle-Béral H; Sutton L; Dessen P; Solary E; Akashi K; Vainchenker W; Mercher T; Droin N; Ogawa S; Nguyen-Khac F; Bernard OA
    Cancer Discov; 2014 Sep; 4(9):1088-101. PubMed ID: 24920063
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.
    Wang L; Brooks AN; Fan J; Wan Y; Gambe R; Li S; Hergert S; Yin S; Freeman SS; Levin JZ; Fan L; Seiler M; Buonamici S; Smith PG; Chau KF; Cibulskis CL; Zhang W; Rassenti LZ; Ghia EM; Kipps TJ; Fernandes S; Bloch DB; Kotliar D; Landau DA; Shukla SA; Aster JC; Reed R; DeLuca DS; Brown JR; Neuberg D; Getz G; Livak KJ; Meyerson MM; Kharchenko PV; Wu CJ
    Cancer Cell; 2016 Nov; 30(5):750-763. PubMed ID: 27818134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of
    Cavallini C; Visco C; Putta S; Rossi D; Mimiola E; Purvis N; Lovato O; Perbellini O; Falisi E; Facco M; Trentin L; Romanelli MG; Semenzato G; Ambrosetti A; Gaidano G; Pizzolo G; Cesano A; Scupoli MT
    Haematologica; 2017 Apr; 102(4):e144-e147. PubMed ID: 27927769
    [No Abstract]   [Full Text] [Related]  

  • 57. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.
    Gentien D; Kosmider O; Nguyen-Khac F; Albaud B; Rapinat A; Dumont AG; Damm F; Popova T; Marais R; Fontenay M; Roman-Roman S; Bernard OA; Stern MH
    Leukemia; 2014 Jun; 28(6):1355-7. PubMed ID: 24434863
    [No Abstract]   [Full Text] [Related]  

  • 58. Spliceosome mutations in hematopoietic malignancies.
    Hahn CN; Scott HS
    Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Value of NOTCH1 Mutations Detection among Chronic Lymphocytic Leukemia Patients.
    Aref S; El-Agder M; Salama O; Abouzeid T; Sabry M
    Asian Pac J Cancer Prev; 2020 May; 21(5):1295-1301. PubMed ID: 32458636
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations.
    Kristensen L; Kristensen T; Abildgaard N; Royo C; Frederiksen M; Mourits-Andersen T; Campo E; Møller MB
    Eur J Haematol; 2016 Aug; 97(2):175-82. PubMed ID: 26558352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.